Switch theme
Sign up to access all valuation multiples
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
2017
30
LTM Revenue $55.0M
LTM EBITDA $7.9M
$519M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eton Pharmaceuticals has a last 12-month revenue (LTM) of $55.0M and a last 12-month EBITDA of $7.9M.
In the most recent fiscal year, Eton Pharmaceuticals achieved revenue of $39.0M and an EBITDA of -$1.5M.
Eton Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eton Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $55.0M | XXX | $39.0M | XXX | XXX | XXX |
| Gross Profit | $34.2M | XXX | $23.4M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $7.9M | XXX | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | -4% | XXX | XXX | XXX |
| EBIT | $5.4M | XXX | -$2.6M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | -7% | XXX | XXX | XXX |
| Net Profit | $0.7M | XXX | -$3.8M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eton Pharmaceuticals's stock price is $19.
Eton Pharmaceuticals has current market cap of $507M, and EV of $519M.
See Eton Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $519M | $507M | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eton Pharmaceuticals has market cap of $507M and EV of $519M.
Eton Pharmaceuticals's trades at 13.3x EV/Revenue multiple, and -357.9x EV/EBITDA.
Equity research analysts estimate Eton Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eton Pharmaceuticals has a P/E ratio of 713.6x.
See valuation multiples for Eton Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $507M | XXX | $507M | XXX | XXX | XXX |
| EV (current) | $519M | XXX | $519M | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBITDA | 66.1x | XXX | -357.9x | XXX | XXX | XXX |
| EV/EBIT | 96.6x | XXX | -199.9x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 713.6x | XXX | -132.5x | XXX | XXX | XXX |
| EV/FCF | 107.8x | XXX | -57.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEton Pharmaceuticals's last 12 month revenue growth is 71%
Eton Pharmaceuticals's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.9M for the same period.
Eton Pharmaceuticals's rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eton Pharmaceuticals's rule of X is 192% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eton Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 71% | XXX | 74% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | 260% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 70% | XXX | 68% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 192% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 67% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eton Pharmaceuticals acquired XXX companies to date.
Last acquisition by Eton Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Eton Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eton Pharmaceuticals founded? | Eton Pharmaceuticals was founded in 2017. |
| Where is Eton Pharmaceuticals headquartered? | Eton Pharmaceuticals is headquartered in United States of America. |
| How many employees does Eton Pharmaceuticals have? | As of today, Eton Pharmaceuticals has 30 employees. |
| Who is the CEO of Eton Pharmaceuticals? | Eton Pharmaceuticals's CEO is Mr. Sean E. Brynjelsen. |
| Is Eton Pharmaceuticals publicy listed? | Yes, Eton Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Eton Pharmaceuticals? | Eton Pharmaceuticals trades under ETON ticker. |
| When did Eton Pharmaceuticals go public? | Eton Pharmaceuticals went public in 2018. |
| Who are competitors of Eton Pharmaceuticals? | Similar companies to Eton Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eton Pharmaceuticals? | Eton Pharmaceuticals's current market cap is $507M |
| What is the current revenue of Eton Pharmaceuticals? | Eton Pharmaceuticals's last 12 months revenue is $55.0M. |
| What is the current revenue growth of Eton Pharmaceuticals? | Eton Pharmaceuticals revenue growth (NTM/LTM) is 71%. |
| What is the current EV/Revenue multiple of Eton Pharmaceuticals? | Current revenue multiple of Eton Pharmaceuticals is 9.4x. |
| Is Eton Pharmaceuticals profitable? | Yes, Eton Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eton Pharmaceuticals? | Eton Pharmaceuticals's last 12 months EBITDA is $7.9M. |
| What is Eton Pharmaceuticals's EBITDA margin? | Eton Pharmaceuticals's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Eton Pharmaceuticals? | Current EBITDA multiple of Eton Pharmaceuticals is 66.1x. |
| What is the current FCF of Eton Pharmaceuticals? | Eton Pharmaceuticals's last 12 months FCF is $4.8M. |
| What is Eton Pharmaceuticals's FCF margin? | Eton Pharmaceuticals's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Eton Pharmaceuticals? | Current FCF multiple of Eton Pharmaceuticals is 107.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
